Perspective Therapeutics, Inc.
CATX
$1.94
$0.094.87%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -36.59% | -29.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -36.59% | -29.85% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -10,658.54% | -29.85% | |||
| SG&A Expenses | 18.22% | 26.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.19% | 28.49% | |||
| Operating Income | -12.13% | -30.65% | |||
| Income Before Tax | -179.11% | -34.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -165.24% | -34.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -165.63% | -29.20% | |||
| EBIT | -12.13% | -30.65% | |||
| EBITDA | -124.76% | -31.22% | |||
| EPS Basic | -164.92% | -21.92% | |||
| Normalized Basic EPS | -19.88% | -27.19% | |||
| EPS Diluted | -431.62% | -21.92% | |||
| Normalized Diluted EPS | -19.88% | -27.19% | |||
| Average Basic Shares Outstanding | 0.27% | 5.97% | |||
| Average Diluted Shares Outstanding | 0.27% | 5.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||